Search the Newsreel

Form 8K EDESA BIOTECH For: 13 August By Investing.com

This article reports that EDESA BIOTECH filed a Form 8K on August 13th, as tracked by Investing.com. The filing details are not provided within the article itself, but it highlights the company EDSA with a stock performance of +2.45%. The piece is primarily a …

Fortress Biotech (FBIO) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Wednesday, Aug. 12, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Co-Founder, President and Chief Executive Officer - Claude MaraouiChief Financial Officer - Joseph BeneschChief Operating Officer and General Counsel - Ramsey AlloushSenior Director of Corporate Operations - Jaclyn …

RTW Biotech Opportunities Ltd USD Revenue Breakdown – GETTEX:0BM

Edesa Biotech (NASDAQ:EDSA) Posts Earnings Results, Misses Expectations By $0.16 EPS

Edesa Biotech (NASDAQ:EDSA) reported a quarterly loss of $0.60 per share, missing analyst expectations by $0.16. Shares traded up $0.13 to $5.43, with a highly volatile one-year range of $0.72 to $20.32. Institutional investors own 5.50% of the stock, and analyst ratings are mixed, …

Fortress Biotech earnings beat by $0.11, revenue fell short of estimates

Fortress Biotech (NASDAQ:FBIO) Posts Earnings Results, Beats Estimates By $0.12 EPS

Fortress Biotech (NASDAQ:FBIO) announced its quarterly earnings, reporting an adjusted loss of $0.08 per share, surpassing the consensus estimate by $0.12. The biopharmaceutical company also exceeded revenue forecasts with $18.72 million. Despite mixed analyst sentiment and a "Hold" consensus rating, institutional investors own a …

Edesa Biotech Inc reports results for the quarter ended June 30 - Earnings Summary

Edesa Biotech Inc has reported its earnings for the quarter that ended on June 30. The article provides a summary of these results. To access the full details, readers are directed to the complete article available through TradingView, which offers unlimited access to Reuters …

Fortress Biotech 2026: Revenue $17.84M, Net income ($2.48M), EPS ($0.08) — 10-Q Summary

Fortress Biotech (FBIO) reported its financial results for the quarter ended in 2026, showing product revenue of $17.84 million, an 18.9% increase year-over-year. Despite the revenue growth, the company recorded a net loss attributable to common stockholders of ($2.48 million) and a diluted loss …

Edesa Biotech Q3 Results: EPS misses estimate, losses widen 140% YoY

Fortress Biotech: Q2 Earnings Snapshot

Moleculin Biotech (NASDAQ: MBRX) advances AML trial but warns on cash

Moleculin Biotech (NASDAQ: MBRX) is progressing with its pivotal Phase 2/3 MIRACLE trial for Annamycin in relapsed/refractory AML, showing promising preliminary efficacy and cardiac safety data. Despite these clinical advancements and a recent $9.3 million equity/warrant offering, the company reported a net loss of …

Edesa Biotech (EDSA) loss widens to $11.9M as R&D surges and cash tightens

Fortress Biotech (NASDAQ: FBIO) gains $158.9M from voucher sale and boosts cash

Edesa Reports $5.4 Million Q3 Loss as EB06 Phase 2 Site Activation Begins

Edesa Biotech (EDSA) reported a net loss of $5.4 million for Q3 2026, an increase from $1.7 million in the prior year, primarily due to rising operating expenses from its Phase 2 EB06 vitiligo study. The company is beginning site activation for this study …

Evotec (NASDAQ:EVO) Issues Earnings Results

Moleculin Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Edesa Biotech Reports Fiscal 3rd Quarter 2026 Results

Edesa Biotech (Nasdaq: EDSA) reported its fiscal third-quarter 2026 results, showing a net loss of $5.4 million due to increased operating expenses. The company announced it has completed preparations for its Phase 2 EB06 vitiligo trial and begun activating initial investigational sites, with patient …

Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Fortress Biotech reported a 14% increase in total net revenue to $18.7 million for Q2 2026 compared to Q2 2025, driven by commercial portfolio growth and advancements in partnered programs. Key highlights include Crystalys Therapeutics' $130 million Series B financing for dotinurad, expansion of …

Crystalys Raises $130M to Advance Its Once-Daily Gout Drug

Fortress Biotech (Nasdaq: FBIO) reported a 14% increase in Q2 2026 net revenue to $18.7 million, primarily driven by dermatology product sales. The company's cash and cash equivalents significantly rose to $196.6 million, aided by the monetization of a ZYCUBO® priority review voucher. Key …

PDS Biotechnology (PDSB) cuts R&D spend but warns on going concern, cash at $5.6M

PDS Biotechnology reported a net loss of $17.1 million for the six months ended June 30, 2026, with cash and cash equivalents significantly reduced to $5.6 million from $26.7 million at year-end 2025. The company's management disclosed substantial doubt about its ability to continue …

XBiotech: Q2 Earnings Snapshot

This article is an earnings snapshot for XBiotech's Q2 performance. It is a placeholder without actual financial details, suggesting that the full earnings report would contain the relevant financial data.

PDSB Maintained by HC Wainwright & Co. -- Price Target Lowered t

AQR group (VRXA) discloses 658,138-share Veraxa Biotech position under 5% threshold

AQR Capital Management, along with its affiliates, has reported a beneficial ownership of 658,138 Ordinary Shares in Veraxa Biotech Holding AG, which includes warrants. This position represents 0.46% of Veraxa’s outstanding Ordinary Shares, confirming that the AQR group holds less than the 5% threshold. …

XBiotech (NASDAQ: XBIT) trims R&D spend yet remains loss-making in Q2 2026

XBiotech Inc. reported a Q2 2026 net loss of $6.7 million and a six-month net loss of $12.2 million, despite significantly reducing research and development and general and administrative expenses. The clinical-stage biopharmaceutical company does not anticipate generating revenue in 2026 and expects continued …

Ajooni Biotech Ltd is Rated Sell

Evotec (NASDAQ:EVO) Shares Gap Down Following Weak Earnings

Evotec (NASDAQ:EVO) shares gapped down following weaker-than-expected quarterly earnings, missing analyst estimates for both EPS and revenue. The company reported a loss of $0.14 per share against an expected $0.05 loss, and revenue of $161.2 million compared to estimates of $173.87 million. This performance …

PDS Biotechnology reports Q2 2026 net loss $9.8M, cash $5.6M, strategic refocus on PDS0301

PDS Biotechnology reported a net loss of $9.8 million for Q2 2026 and had $5.6 million in cash at quarter-end. The company announced a strategic refocus to prioritize its tumor-targeted IL-12 program, PDS0301, and will discontinue internal investment in PDS0101, seeking external partnerships for …

Evotec stock falls as 2026 guidance is cut after weak Q2 results

Evotec's stock fell sharply after the company reported weaker-than-expected Q2 2026 results and significantly cut its full-year 2026 revenue and profit guidance. Group revenue declined by 16.2% year-over-year, and adjusted EBITDA fell to a loss of €20.8 million, prompting a reduction in the 2026 …

Evotec SE Stock 12‑Month Price Target Cut to $2.75, Implies 26% Upside

Evotec SE's average 12-month price target has been reduced from $3.01 to $2.75 by 9 analysts, with a range of $2 to $5.77 per share. This new target implies a potential upside of approximately 26% based on the August 12 closing price. Despite the …

HC Wainwright Has Pessimistic Outlook of SANA Q3 Earnings

HC Wainwright has lowered its Q3 2026 earnings forecast for Sana Biotechnology (NASDAQ:SANA) to a loss of $0.14 per share, anticipating continued losses through future fiscal years. Despite this, Sana's last quarterly loss of $0.13 per share exceeded analyst expectations. The stock currently holds …

PDS Biotechnology: Q2 Earnings Snapshot

PDS Biotech Reports Second Quarter 2026 Financial Results

PDS Biotechnology Corporation announced its financial results for the second quarter ended June 30, 2026, reporting a net loss of $9.8 million. The company also provided a clinical and corporate update, highlighting positive clinical data for PDS0301 in metastatic colorectal cancer and announcing a …

Avecho Biotechnology Limited (ASX:AVE) Share Price Remains Unchanged as Stock Trades Within Daily Range

Krystal Biotech (KRYS) Earnings And Pipeline Progress Put Valuation Back In Focus

Krystal Biotech (KRYS) reported strong Q2 2026 earnings with net income of US$54.77 million and 24% net product revenue growth for VYJUVEK, leading to a significant year-to-date share price return. Despite a recent short-term decline, the company is trading below analyst price targets, and …

Evotec (EVO) slashes 2026 outlook as losses widen and revenue drops 19%

Evotec SE reported a significant downturn in its first half of 2026 financial results, with group revenue decreasing by 19.2% to €300.1 million and net loss widening to €168.6 million. The company has consequently revised its full-year 2026 guidance downwards, now expecting revenue between …

Evotec affirms FY26 sales guidance of $667M-$714M vs estimate

Evotec has reaffirmed its full-year 2026 sales guidance, maintaining the revenue range of $667.470 million to $714.310 million. This outlook exceeds the consensus estimate of $673.750 million at the lower bound, signaling stability in its near-term financial projections. The company's decision to keep the …